M. Savino, S. Santhakumaran, C. Currie, B. Onggo, Katharine M Evans, J. Medcalf, D. Nitsch, R. Steenkamp
Introduction: This retrospective cohort study compares in-centre haemodialysis (ICHD) patients’ outcomes between the 1st and 2nd waves of the COVID-19 pandemic in England, Wales, and Northern Ireland. Methods: All people aged ≥18 years receiving ICHD at 31 December 2019, who were still alive and not in receipt of a kidney transplant at 1 March and who had a positive polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 31 January 2021, were included. The COVID-19 infections were split into two “waves”: wave 1 from March to August 2020 and wave 2 from September 2020 to January 2021. Cumulative incidence of COVID-19, multivariable Cox models for risk of positivity, median, and 95% credible interval of reproduction number in dialysis units were calculated separately for wave 1 and wave 2. Survival and hazard ratios for mortality were described with age- and sex-adjusted Kaplan-Meier plots and multivariable Cox proportional models. Results: 4,408 ICHD patients had COVID-19 during the study period. Unadjusted survival at 28 days was similar in both waves (wave 1 75.6% [95% confidence interval [CI]: 73.7–77.5], wave 2 76.3% [95% CI 74.3–78.2]), but death occurred more rapidly after detected infection in wave 1. Long vintage treatment and not being on the transplant waiting list were associated with higher mortality in both waves. Conclusions: Risk of death of patients on ICHD treatment with COVID-19 remained unchanged between the first and second outbreaks. This highlights that this vulnerable patient group needs to be prioritized for interventions to prevent severe COVID-19, including vaccination, and the implementation of measures to reduce the risk of transmission alone is not sufficient.
{"title":"Comparison of Outcomes of In-Centre Haemodialysis Patients between the 1st and 2nd COVID-19 Outbreak in England, Wales, and Northern Ireland: A UK Renal Registry Analysis","authors":"M. Savino, S. Santhakumaran, C. Currie, B. Onggo, Katharine M Evans, J. Medcalf, D. Nitsch, R. Steenkamp","doi":"10.1159/000523731","DOIUrl":"https://doi.org/10.1159/000523731","url":null,"abstract":"Introduction: This retrospective cohort study compares in-centre haemodialysis (ICHD) patients’ outcomes between the 1st and 2nd waves of the COVID-19 pandemic in England, Wales, and Northern Ireland. Methods: All people aged ≥18 years receiving ICHD at 31 December 2019, who were still alive and not in receipt of a kidney transplant at 1 March and who had a positive polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 31 January 2021, were included. The COVID-19 infections were split into two “waves”: wave 1 from March to August 2020 and wave 2 from September 2020 to January 2021. Cumulative incidence of COVID-19, multivariable Cox models for risk of positivity, median, and 95% credible interval of reproduction number in dialysis units were calculated separately for wave 1 and wave 2. Survival and hazard ratios for mortality were described with age- and sex-adjusted Kaplan-Meier plots and multivariable Cox proportional models. Results: 4,408 ICHD patients had COVID-19 during the study period. Unadjusted survival at 28 days was similar in both waves (wave 1 75.6% [95% confidence interval [CI]: 73.7–77.5], wave 2 76.3% [95% CI 74.3–78.2]), but death occurred more rapidly after detected infection in wave 1. Long vintage treatment and not being on the transplant waiting list were associated with higher mortality in both waves. Conclusions: Risk of death of patients on ICHD treatment with COVID-19 remained unchanged between the first and second outbreaks. This highlights that this vulnerable patient group needs to be prioritized for interventions to prevent severe COVID-19, including vaccination, and the implementation of measures to reduce the risk of transmission alone is not sufficient.","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"22 1","pages":"1 - 12"},"PeriodicalIF":0.0,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74928668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Soohoo, L. Hashemi, Jui-Ting Hsiung, H. Moradi, M. Budoff, C. Kovesdy, K. Kalantar-Zadeh, E. Streja
Background: Previous studies have suggested that metabolic syndrome (MetS) components are associated with renal outcomes, defined as a decline in kidney function or reaching end-stage renal disease (ESRD). Elevated triglycerides (TGs) are a component of MetS that have been reported to be associated with renal outcomes. However, the association of TGs with renal outcomes in chronic kidney disease (CKD) patients independent of the other components of the MetS remains understudied. Methods: We examined 1,657,387 patients with data on TGs and other components of MetS in 2004–2006 and followed up until 2014. Patients with ESRD on renal replacement therapy were excluded. We examined time to ESRD, estimated glomerular filtration rate (eGFR) slope (renal function decline), and time to incident CKD (eGFR <60 mL/min/1.73 m2) among baseline normal kidney function (non-CKD) patients, using Cox or logistic regression, adjusted for clinical characteristics and MetS components. We also stratified analyses by the number of MetS components. Results: The cohort was on average 64 years old and comprised 5% females, 15% African Americans, and 24% with nondialysis-dependent CKD. Among non-CKD patients, the adjusted relationship of TGs with time to incident CKD was strong and linear. Compared to TGs 120–<160 mg/dL, higher TGs were associated with a faster renal function decline across all CKD stages. Elevated TGs ≥240 mg/dL were associated with a faster time to ESRD among non-CKD and CKD stages 3A–3B, while the risk gradually declined to null or lower in CKD stages 4–5. Models were robust after MetS component adjustment and stratification. Conclusion: Independent of MetS components, high TGs levels were associated with a higher incidence of CKD and a faster renal function decline, yet showed no or inverse associations with time to ESRD in CKD stages 4–5. Examining the effects of TGs-lowering interventions on incident CKD and kidney preserving therapy warrants further studies including clinical trials.
{"title":"Association of Serum Triglycerides and Renal Outcomes among 1.6 Million US Veterans","authors":"M. Soohoo, L. Hashemi, Jui-Ting Hsiung, H. Moradi, M. Budoff, C. Kovesdy, K. Kalantar-Zadeh, E. Streja","doi":"10.1159/000522388","DOIUrl":"https://doi.org/10.1159/000522388","url":null,"abstract":"Background: Previous studies have suggested that metabolic syndrome (MetS) components are associated with renal outcomes, defined as a decline in kidney function or reaching end-stage renal disease (ESRD). Elevated triglycerides (TGs) are a component of MetS that have been reported to be associated with renal outcomes. However, the association of TGs with renal outcomes in chronic kidney disease (CKD) patients independent of the other components of the MetS remains understudied. Methods: We examined 1,657,387 patients with data on TGs and other components of MetS in 2004–2006 and followed up until 2014. Patients with ESRD on renal replacement therapy were excluded. We examined time to ESRD, estimated glomerular filtration rate (eGFR) slope (renal function decline), and time to incident CKD (eGFR <60 mL/min/1.73 m2) among baseline normal kidney function (non-CKD) patients, using Cox or logistic regression, adjusted for clinical characteristics and MetS components. We also stratified analyses by the number of MetS components. Results: The cohort was on average 64 years old and comprised 5% females, 15% African Americans, and 24% with nondialysis-dependent CKD. Among non-CKD patients, the adjusted relationship of TGs with time to incident CKD was strong and linear. Compared to TGs 120–<160 mg/dL, higher TGs were associated with a faster renal function decline across all CKD stages. Elevated TGs ≥240 mg/dL were associated with a faster time to ESRD among non-CKD and CKD stages 3A–3B, while the risk gradually declined to null or lower in CKD stages 4–5. Models were robust after MetS component adjustment and stratification. Conclusion: Independent of MetS components, high TGs levels were associated with a higher incidence of CKD and a faster renal function decline, yet showed no or inverse associations with time to ESRD in CKD stages 4–5. Examining the effects of TGs-lowering interventions on incident CKD and kidney preserving therapy warrants further studies including clinical trials.","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"84 1","pages":"457 - 468"},"PeriodicalIF":0.0,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76962604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Smith, A. Croft, H. Morris, A. Naylor, D. Huso, C. Isacke, Caroline O. S. Savage, C. Buckley
Background: Tissue fibrosis and microvascular rarefaction are hallmarks of progressive renal disease. CD248 is a transmembrane glycoprotein expressed by key effector cells within the stroma of fibrotic kidneys including pericytes, myofibroblasts and stromal fibroblasts. In human disease, increased expression of CD248 by stromal cells predicts progression to end-stage renal failure. We therefore, hypothesized that the genetic deletion of the CD248 gene would protect against fibrosis following kidney injury. Methods: Using the unilateral ureteral obstruction (UUO) model of renal fibrosis, we investigated the effect of genetic deletion of CD248 on post obstructive kidney fibrosis. Results: CD248 null mice were protected from fibrosis and microvascular rarefaction following UUO. Although the precise mechanism is not known, this may to be due to a stabilizing effect of pericytes with less migration and differentiation of pericytes toward a myofibroblast phenotype in CD248-/- mice. CD248-/- fibroblasts also proliferated less and deposited less collagen in vitro. Conclusion: These studies suggest that CD248 stromal cells have a pathogenic role in renal fibrosis and that targeting CD248 is effective at inhibiting both microvascular rarefaction and renal fibrosis through modulation of pericyte and stromal cell function.
{"title":"Genetic Deletion of the Stromal Cell Marker CD248 (Endosialin) Protects against the Development of Renal Fibrosis","authors":"S. Smith, A. Croft, H. Morris, A. Naylor, D. Huso, C. Isacke, Caroline O. S. Savage, C. Buckley","doi":"10.1159/000438754","DOIUrl":"https://doi.org/10.1159/000438754","url":null,"abstract":"Background: Tissue fibrosis and microvascular rarefaction are hallmarks of progressive renal disease. CD248 is a transmembrane glycoprotein expressed by key effector cells within the stroma of fibrotic kidneys including pericytes, myofibroblasts and stromal fibroblasts. In human disease, increased expression of CD248 by stromal cells predicts progression to end-stage renal failure. We therefore, hypothesized that the genetic deletion of the CD248 gene would protect against fibrosis following kidney injury. Methods: Using the unilateral ureteral obstruction (UUO) model of renal fibrosis, we investigated the effect of genetic deletion of CD248 on post obstructive kidney fibrosis. Results: CD248 null mice were protected from fibrosis and microvascular rarefaction following UUO. Although the precise mechanism is not known, this may to be due to a stabilizing effect of pericytes with less migration and differentiation of pericytes toward a myofibroblast phenotype in CD248-/- mice. CD248-/- fibroblasts also proliferated less and deposited less collagen in vitro. Conclusion: These studies suggest that CD248 stromal cells have a pathogenic role in renal fibrosis and that targeting CD248 is effective at inhibiting both microvascular rarefaction and renal fibrosis through modulation of pericyte and stromal cell function.","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"26 1","pages":"265 - 277"},"PeriodicalIF":0.0,"publicationDate":"2015-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90533247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic Kidney Disease and Hypertension A. Levin, Vancouver, B.C. R. Gansevoort, Groningen Acute Kidney Injury R. Mehta, San Diego, Calif. N. Kolhe, Derby Dialysis J. Daugirdas, Chicago, Ill. C. Hutchison, Hawkes Bay C. Fraansen, Groningen Patient Subjective Experience, Healthcare Delivery and Innovation in Practice R. Fluck, Derby E. Brown, London Crossover States with Non-Renal Organ Systems C. Chan, Toronto, Ont. T. Breidthardt, Basel N. Selby, Derby Transplantation A. Chandraker, Boston, Mass. A. Salama, London Editor-in-Chief
慢性肾脏疾病和高血压A. Levin，温哥华，bc . R. Gansevoort，格罗宁根急性肾损伤R. Mehta，圣地亚哥，加州N. Kolhe，德比透析J. Daugirdas，芝加哥，伊利诺伊州C. Hutchison, Hawkes Bay C. Fraansen, Groningen患者主观体验，医疗保健服务和创新实践R. Fluck, Derby E. Brown, London非肾器官系统的跨界状态C. Chan，多伦多，安大略省T. Breidthardt，巴塞尔N.塞尔比，德比移植A.钱德拉克，波士顿，马萨诸塞州A.萨拉马，伦敦总编
{"title":"Contents Vol. 128, 2014","authors":"M. Nahas","doi":"10.1159/000375514","DOIUrl":"https://doi.org/10.1159/000375514","url":null,"abstract":" Chronic Kidney Disease and Hypertension A. Levin, Vancouver, B.C. R. Gansevoort, Groningen Acute Kidney Injury R. Mehta, San Diego, Calif. N. Kolhe, Derby Dialysis J. Daugirdas, Chicago, Ill. C. Hutchison, Hawkes Bay C. Fraansen, Groningen Patient Subjective Experience, Healthcare Delivery and Innovation in Practice R. Fluck, Derby E. Brown, London Crossover States with Non-Renal Organ Systems C. Chan, Toronto, Ont. T. Breidthardt, Basel N. Selby, Derby Transplantation A. Chandraker, Boston, Mass. A. Salama, London Editor-in-Chief","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"128 1","pages":"I - VI"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000375514","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64772665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Peters, R. Masereeuw, P. Pickkers, N. Srisawat, R. Mehta, P. Sanders, A. Agarwal, R. Murugan, J. Kellum, J. Gigliotti, M. Okusa, Timothy N Ball, C. Ince, F. Garzotto, D. McKay, Sashi G. Kasimsetty, Sean E. DeWolf, A. Shigeoka, S. Noel, Maria N. Martina-Lingua, S. Bandapalle, J. Pluznick, A. Hamad, D. A. Peterson, P. McCullough, P. Devarajan, P. Murray, H. Rabb, M. Zanella, C. Ronco, Susanne V. Fleig, B. Humphreys, Liyu He, M. Livingston, Zheng Dong, Z. Endre, Aneley Hundae, E. Abdel-Rahman, M. Godin, E. Macedo, Isaah S. Vincent, D. Portilla, S. Bandapalle, A. Hamad, Aashish Sharma, Marìa Jimena Mucino, Mei T. Tran, S. Parikh, F. Billings, A. Shaw, Kelly K. Andringa, A. Schneider, S. Bagshaw, S. Goldstein, Kathleen D. Liu, J. Bonventre, Michael Heung, L. Chawla, R. Zager, Ali C. M. Johnson, V. Vallon, Noureddin Nourbakhsh, Prabhleen Singh, H. Shin, H. Rabb, M. Martina, S. Noel, Satz Mengensatzproduktion, Druckerei Stückle
Chronic Kidney Disease and Hypertension A. Levin, Vancouver, B.C. R. Gansevoort, Groningen Acute Kidney Injury R. Mehta, San Diego, Calif. N. Kolhe, Derby Dialysis J. Daugirdas, Chicago, Ill. C. Hutchison, Hawkes Bay C. Fraansen, Groningen Patient Subjective Experience, Healthcare Delivery and Innovation in Practice R. Fluck, Derby E. Brown, London Crossover States with Non-Renal Organ Systems C. Chan, Toronto, Ont. T. Breidthardt, Basel N. Selby, Derby Transplantation A. Chandraker, Boston, Mass. A. Salama, London Editor-in-Chief
慢性肾脏疾病和高血压A. Levin，温哥华，bc . R. Gansevoort, Groningen急性肾损伤R. Mehta，圣地亚哥，加州N. Kolhe，德比透析J. Daugirdas，芝加哥，伊利诺伊州C. Hutchison, Hawkes Bay C. Fraansen, Groningen患者主观体验，医疗服务的创新实践R. Fluck, Derby E. Brown，伦敦非肾器官系统的交叉状态C. Chan，多伦多，Ont。T. Breidthardt，巴塞尔N.塞尔比，德比移植A.钱德拉克，波士顿，马萨诸塞州A.萨拉马，伦敦总编
{"title":"Contents Vol. 127, 2014","authors":"E. Peters, R. Masereeuw, P. Pickkers, N. Srisawat, R. Mehta, P. Sanders, A. Agarwal, R. Murugan, J. Kellum, J. Gigliotti, M. Okusa, Timothy N Ball, C. Ince, F. Garzotto, D. McKay, Sashi G. Kasimsetty, Sean E. DeWolf, A. Shigeoka, S. Noel, Maria N. Martina-Lingua, S. Bandapalle, J. Pluznick, A. Hamad, D. A. Peterson, P. McCullough, P. Devarajan, P. Murray, H. Rabb, M. Zanella, C. Ronco, Susanne V. Fleig, B. Humphreys, Liyu He, M. Livingston, Zheng Dong, Z. Endre, Aneley Hundae, E. Abdel-Rahman, M. Godin, E. Macedo, Isaah S. Vincent, D. Portilla, S. Bandapalle, A. Hamad, Aashish Sharma, Marìa Jimena Mucino, Mei T. Tran, S. Parikh, F. Billings, A. Shaw, Kelly K. Andringa, A. Schneider, S. Bagshaw, S. Goldstein, Kathleen D. Liu, J. Bonventre, Michael Heung, L. Chawla, R. Zager, Ali C. M. Johnson, V. Vallon, Noureddin Nourbakhsh, Prabhleen Singh, H. Shin, H. Rabb, M. Martina, S. Noel, Satz Mengensatzproduktion, Druckerei Stückle","doi":"10.1159/000367960","DOIUrl":"https://doi.org/10.1159/000367960","url":null,"abstract":"Chronic Kidney Disease and Hypertension A. Levin, Vancouver, B.C. R. Gansevoort, Groningen Acute Kidney Injury R. Mehta, San Diego, Calif. N. Kolhe, Derby Dialysis J. Daugirdas, Chicago, Ill. C. Hutchison, Hawkes Bay C. Fraansen, Groningen Patient Subjective Experience, Healthcare Delivery and Innovation in Practice R. Fluck, Derby E. Brown, London Crossover States with Non-Renal Organ Systems C. Chan, Toronto, Ont. T. Breidthardt, Basel N. Selby, Derby Transplantation A. Chandraker, Boston, Mass. A. Salama, London Editor-in-Chief","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"127 1","pages":"I - IV"},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000367960","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64743094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important fi ndings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. Th e Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. Th e Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. Th e Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. Th e Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text fi le. Illustration data must be stored as separate fi les. Do not integrate fi gures into the text. Electronically submitted b/w half-tone and color illustrations must have a fi nal resolution of 300 dpi aft er scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and fi gure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. Th e list of references should include only those publications which are cited in the text. Number references in the order in which they are fi rst mentioned in the text; do not list alphabetically. Th e surnames of the authors followed by initials should be given. Th ere should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcifi cation in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Th eoharides TC, Boucher W, Spear K: Serum interleukin-6 refl ects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger,
{"title":"Front & Back Matter","authors":"Z.-H. Liu, J. He","doi":"10.1159/000369240","DOIUrl":"https://doi.org/10.1159/000369240","url":null,"abstract":"Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important fi ndings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. Th e Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. Th e Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. Th e Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. Th e Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text fi le. Illustration data must be stored as separate fi les. Do not integrate fi gures into the text. Electronically submitted b/w half-tone and color illustrations must have a fi nal resolution of 300 dpi aft er scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and fi gure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. Th e list of references should include only those publications which are cited in the text. Number references in the order in which they are fi rst mentioned in the text; do not list alphabetically. Th e surnames of the authors followed by initials should be given. Th ere should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcifi cation in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Th eoharides TC, Boucher W, Spear K: Serum interleukin-6 refl ects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, ","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"127 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000369240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64751425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited b
{"title":"Front & Back Matter","authors":"A. Benigni, P. Romagnani, G. Remuzzi","doi":"10.1159/000366181","DOIUrl":"https://doi.org/10.1159/000366181","url":null,"abstract":"Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited b","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000366181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64737061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited b
{"title":"Front & Back Matter","authors":"C. McIntyre, S. Beesley","doi":"10.1159/000365317","DOIUrl":"https://doi.org/10.1159/000365317","url":null,"abstract":"Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited b","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000365317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64729334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：